C4 Therapeutics Teams Up with Pfizer on New Myeloma Combo Trial
DENVER, Colo., Oct 01, 2025 (247marketnews.com)- C4 Therapeutics (NASDAQ:CCCC) announced a clinical trial collaboration and supply agreement with Pfizer (NYSE:PFE) to evaluate a novel drug combination for relapsed/refractory multiple myeloma (RRMM). The trial will pair C4T’s IKZF1/3 degrader cemsidomide with Pfizer’s BCMAxCD3 bispecific antibody elranatamab (marketed as ELREXFIO).
Under the agreement, Pfizer will provide elranatamab at no cost, while C4T will sponsor and conduct a Phase 1b trial set to begin in Q2 2026. The study will explore the safety and tolerability of combining cemsidomide and dexamethasone with elranatamab as a second-line or later treatment for RRMM.
C4T’s early data on cemsidomide in multiple myeloma showed strong T-cell activation and cytokine expression, suggesting potential synergy when combined with a T-cell engaging therapy like elranatamab. The upcoming trial aims to determine an optimal dosing strategy for the combination.
C4T CEO Andrew Hirsch called the collaboration an opportunity to potentially improve outcomes in earlier lines of therapy, especially as elranatamab is “on the path to potentially becoming a standard of care.”
The partnership gives C4 Therapeutics a strategic boost by aligning its targeted protein degradation approach with one of Pfizer’s most advanced immuno-oncology assets, potentially opening the door for more durable, deeper responses in a tough-to-treat patient population.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com